Eloxx Pharmaceuticals, Inc.
ELOX · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | 0.16 | 0.01 |
| FCF Yield | -26.10% | -24.01% | -125.31% | -143.58% |
| EV / EBITDA | -4.48 | -2.64 | -1.22 | 0.34 |
| Quality | ||||
| ROIC | 25.45% | 33.15% | 54.52% | -221.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.48 | 1.09 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -66.99% | 69.68% | -20.37% | 19.06% |
| Safety | ||||
| Net Debt / EBITDA | -0.31 | -0.45 | -0.24 | 1.05 |
| Interest Coverage | -15.48 | -18.00 | -11.31 | -10.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |